Open AccessInternal quality control status for BNP and NT ‐pro BNP in China from 2014 to 2017
Author(s) -
Sun Huizhen,
Wang Wei,
Zhao Haijian,
Zhang Chuanbao,
He Falin,
Zhong Kun,
Yuan Shuai,
Wang Zhiguo
Publication year - 2019
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22643
Subject(s) - medicine , external quality assessment , cardiology , pathology
Background This study aimed to investigate and analyze the status of internal quality control ( IQC ) for BNP and NT ‐pro BNP from 2014 to 2017, so as to have an integral understanding of quality performance of measurement in clinical laboratories in China. Methods The 4‐year IQC information for BNP and NT ‐pro BNP of participant laboratories were collected through EQA reporting system. Percentages of laboratories meeting different quality requirements (pass rates) for current coefficient of variations ( CV s) were calculated afterwards. Further analysis for current CV s and pass rates among different years and measurement systems were conducted. Finally, we analyzed and summarized IQC practice and its changes in 4 years. Results The current CV s for BNP and NT ‐pro BNP have decreased significantly from 2014 to 2017, and pass rates both presented significant increasing trends. NT ‐pro BNP had higher pass rates than BNP regardless of 1/3 TE a or 1/4 TE a specification was used. The main measurement systems for two analytes were different. For NT ‐pro BNP , current CV s of Roche has decreased significantly among 4 years and were significantly lower than Radiometer and BioMérieux in 2015. Current CV s of Abbott also had decreasing tendency for BNP . Analysis of IQC practice indicated that control rules and IQC frequency had made great progress in 4 years. Conclusion The imprecision performance of measurement of BNP and NT ‐pro BNP has improved with decreasing of current CV s and increasing of pass rates in 4 years. However, it still needs continual improvement. Clinical laboratories in China should take active actions to promote performance of BNP and NT ‐pro BNP measurement.